Pseudoexfoliation may be a risk factor for peripheral vascular disease

Article

Cataract and pseudoexfoliation (PEX) patients with a low ankle brachial index (ABI) are at higher risk of peripheral vascular disease (PVD)

Cataract and pseudoexfoliation (PEX) patients with a low ankle brachial index (ABI) are at higher risk of peripheral vascular disease (PVD), according to a study in Eye.

Dr M.R. Praveen et al., Iladevi Cataract and IOL Research Center, Ahmedabad, India, conducted an observational age-matched case-control study of 160 age-related cataract patients who were no less than 60 years old. Forty PEX patients with cataracts were compared with a control group of 120 cataract patients without PEX. The subjects medical history such as hypertension, diabetes mellitus, cerebrovascular stroke and ischaemic heart disease were taken into consideration.

The risk of PVD among the patients was determined through the measurement of ABI by colour Doppler imaging of the brachia and dorsalis pedis artery. From prio knowledge that a low ABI indicates an increased risk of PVD each patient's lowest mean ABI was recorded as the main outcome measure.

The lowest ABI in the controls was 0.98±0.03 and 0.88±0.02 in the PEX group. It was found that there was a strong correlation between presence of PEX and ABI, with the odds of low ABI being 150 times more than the control group.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.